TFRC and ovarian carcinoma: Tfr1 as a therapeutic target shows promise in ovarian cancer due to previous studies demonstrating an increased expression of Tfr1 receptors in malignant ovarian cancer cells as compared with non-malignant tissue [141], in addition to increased intracellular iron stores in neoplastic cells.